ArticleCancer medicine2019
Competing-risks model for predicting the prognosis of penile cancer based on the SEER database.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Impact of prolonged surgical waiting time on cancer-specific mortality in stage I-II pancreatic ductal adenocarcinoma patients who received radical resection.Journal of gastrointestinal oncology · 2024Article
- Risk factors for distant metastasis and prognosis of the penile cancer with distant metastasis.Translational andrology and urology · 2024Article
- Developing and validating a nomogram for penile cancer survival: A comprehensive study based on SEER and Chinese data.Cancer medicine · 2024Article
- The hepatocellular carcinoma risk in patients with HBV-related cirrhosis: a competing risk nomogram based on a 4-year retrospective cohort study.Frontiers in oncology · 2024Article
- New findings in prognostic factor assessment for adenocarcinoma of transverse colon: a comparison study between competing-risk and COX regression analysis.Frontiers in medicine · 2024Article
- Development and validation of a predictive model for penile cancer based on the surveillance, epidemiology, and end results database and multi-center cases.Journal of cancer research and clinical oncology · 2023Article
- How to use the Surveillance, Epidemiology, and End Results (SEER) data: research design and methodology.Military Medical Research · 2023Review
- Prediction of death probability in adenocarcinoma of the transverse colon: competing-risk nomograms based on 21,469 patients.Journal of cancer research and clinical oncology · 2023Article
- Impact of marital status on overall survival in patients with early-stage hepatocellular carcinoma.Scientific reports · 2022Article
- The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan.Head & neck · 2022Article
- Sleep Duration and Frailty Risk among Older Adults: Evidence from a Retrospective, Population-Based Cohort Study.The journal of nutrition, health & aging · 2022Article
- Survival Comparison Between Squamous Cell Carcinoma and Adenocarcinoma for Radiotherapy-Treated Patients with Stage IIB-IVA Cervical Cancer.Frontiers in oncology · 2022Article
- Data mining in clinical big data: the frequently used databases, steps, and methodological models.Military Medical Research · 2021Review
- Competing-risks nomogram for predicting cancer-specific death in upper tract urothelial carcinoma: a population-based analysis.BMJ open · 2021Observational
- Competing-risks nomograms for predicting cause-specific mortality in parotid-gland carcinoma: A population-based analysis.Cancer medicine · 2021Article
- Prognostic Values of Different Clinicopathological Factors and Predictive Models for Penile Carcinoma.Cancer management and research · 2021Article
- Incidence trends and survival outcomes of penile squamous cell carcinoma: evidence from the Surveillance, Epidemiology and End Results population-based data.Annals of translational medicine · 2020Article
- Nomograms to predict overall and cancer-specific survival in patients with penile cancer.Translational cancer research · 2020Article
- Review
- Competing-risks model for predicting the prognosis of penile cancer based on the SEER database.Cancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThis study performed a competing-risks analysis using data from the SEER database on penile cancer patients with the aim of identifying more accurate prognostic factors.
methodsData on patients with penile cancer were extracted from the SEER database. A univariate analysis used the cumulative incidence function and Gray's test, while multivariate analysis was performed using the Fine-Gray model. Cumulative hazards were compared with a competing-risks model constructed using Kaplan-Meier estimation.
resultsThe multivariate Fine-Gray analysis indicated that being black (HR = 1.51, 95%CI: 1.10-2.07, P = .01), AJCC stage II (HR = 1.94, 95%CI: 1.36-2.77, P < .001), AJCC stage III (HR = 1.98, 95%CI: 1.34-2.91, P < .001), tumor size > 5 cm (HR = 2.23, 95%CI: 1.33-3.72, P < .05), and TNM stages N1 (HR = 2.49, 95%CI: 1.71-3.61, P < .001), N2 (HR = 3.25, 95%CI: 2.18-4.84, P < .001), N3 (HR = 5.05, 95%CI: 2.69-9.50, P < .001), and M1 (HR = 2.21, 95%CI: 1.28-3.84, P < .05) were statistically significant. The results obtained using multivariate Cox regression were different, while Kaplan-Meier curve analysis led to an overestimation of the cumulative risk of the patient.
conclusionsThis study established a competing-risks analysis model for the first time based on the SEER database for the risk assessment of penile cancer patients. The results may help clinicians to better understand penile cancer and provide these patients with more appropriate support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.